OMERS ADMINISTRATION Corp Has $2.75 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• OMERS ADMINISTRATION Corp reduced its stake in Regeneron Pharmaceuticals by 12.8%, owning 4,340 shares valued at $2.75 million after selling 639 shares in the first quarter.
• Regeneron reported $12.89 earnings per share for the last quarter, exceeding analysts' estimates by $4.46, with revenue of $3.68 billion, up 3.6% from the previous year.
• The company announced a quarterly dividend of $0.88 per share, with an annualized yield of 0.6%, set to be paid to investors of record on August 18.

OMERS ADMINISTRATION Corp trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,340 shares of the biopharmaceutical company's stock after selling 639 shares during the period. OMERS ADMINISTRATION Corp's holdings in Regeneron Pharmaceuticals were worth $2,753,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Sanford C. Bernstein increased their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a report on Wednesday, August 27th. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Finally, Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Down 2.2%

NASDAQ:REGN traded down $12.71 during trading hours on Wednesday, reaching $565.19. The company's stock had a trading volume of 589,904 shares, compared to its average volume of 1,100,075. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company has a market cap of $59.90 billion, a price-to-earnings ratio of 14.25, a price-to-earnings-growth ratio of 1.93 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,182.31. The business's 50-day moving average is $559.74 and its 200-day moving average is $586.24.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $11.56 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.